anti-CD97 antibody-drug conjugate

The anti-CD97 antibody-drug conjugate (ADC) is a research-stage biologic developed by investigators at New York University (NYU). It consists of a human IgG1-formatted antibody targeting CD97 (Cluster of Differentiation 97, also known as adhesion G protein-coupled receptor E5 / ADGRE5), conjugated to the cytotoxic payload monomethyl auristatin F (MMAF), a cell-impermeable cytoskeletal polymerization blocker. The antibody binds the CD97 GPCR autoproteolysis-inducing (GAIN) domain with nanomolar affinity and high selectivity, and is efficiently internalized by target cancer cells, enabling direct intracellular delivery of the cytotoxic payload. It has demonstrated efficacy in vitro against acute myeloid leukemia (AML) and glioblastoma multiforme (GBM) cell lines and patient-derived GBM stem cells, with minimal toxicity to healthy cells. CD97 is expressed across all GBM subtypes and most AML genetic subtypes, and also in breast, thyroid, gastric, and prostate carcinomas. NYU has filed a U.S. non-provisional patent application covering the ADC compositions and methods of use.

Other names

anti-CD97-MMAF ADCanti-CD-97-MMAF ADCanti-CD 97-MMAF ADC